Search results for "target vessel"

showing 7 items of 7 documents

Predictors of scaffold failure and impact of optimized scaffold implantation technique on outcome: Results from the German-Austrian ABSORB RegIstRy.

2021

Aims We aimed to investigate predictors of scaffold failure and the potential impact of an optimized scaffold implantation technique by means of a learning curve on long-term clinical outcome after bioresorbable scaffold (BRS) implantation and to evaluate predictors of scaffold failure. Methods and results A total of 3326 patients were included in this prospective, observational, multi-center study (ClinicalTrials.gov NCT02066623) of consecutive patients undergoing BRS implantation between November 2013 and January 2016. The 3144 patients completed follow-up after 24 months, 3265 patients were eligible for time-to-event-analysis. Clinical endpoints were major adverse cardiac events-a compos…

Scaffoldmedicine.medical_specialtyTime FactorsTarget vessel revascularizationCoronary Artery Disease030204 cardiovascular system & hematologyProsthesis Design03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionAbsorbable ImplantsmedicineClinical endpointHumansRadiology Nuclear Medicine and imaging030212 general & internal medicineMyocardial infarctionProspective StudiesRegistriesbusiness.industryGeneral Medicinemedicine.diseaseThrombosisSurgeryTreatment OutcomeAustriaObservational studyCardiology and Cardiovascular MedicinebusinessBioresorbable scaffoldMaceCatheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventionsREFERENCES
researchProduct

Feasibility of Implanting 50-60 mm-Tapered Drug Eluting Stents in Chronic Total Occlusions.

2018

Abstract Background Percutaneous coronary intervention (PCI) of chronic total occlusions (CTO) usually involves multiple overlapping stents implantation to cover long coronary segments. A higher rate of restenosis has been described with stent overlapping. Recently, new long tapered stents emerged as a potential tool for treating long coronary lesions. Feasibility of using these new devices for the CTO PCI has not been described. The aim of this work was to describe our initial experience with 50 and 60 mm-long tapered sirolimus-eluting stents (SES) in CTO PCI. Methods We included 54 consecutive patients who underwent a CTO PCI and in whom an attempt to implant a 50 or 60 mm-long tapered SE…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentTarget vessel030204 cardiovascular system & hematologyProsthesis DesignCoronary Restenosis03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRestenosismedicineHumanscardiovascular diseases030212 general & internal medicineVascular PatencyAgedRetrospective StudiesSirolimusbusiness.industryPercutaneous coronary interventionStentCardiovascular AgentsDrug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseSurgerysurgical procedures operativeTreatment OutcomeCoronary OcclusionConventional PCIChronic DiseaseFeasibility StudiesFemaleImplantCardiology and Cardiovascular MedicinebusinessCardiovascular revascularization medicine : including molecular interventions
researchProduct

A 12-Year Experience With Chimney and Periscope Grafts for Treatment of Type I Endoleaks.

2015

Purpose: To evaluate the midterm outcomes of chimney and/or periscope grafts (CPGs) in patients presenting type I endoleak after a previous endovascular aneurysm repair (EVAR). Methods: Between June 2002 and April 2014, 24 consecutive patients (mean age 73.9±9.2 years; 23 men) presenting a type I endoleak were addressed with CPGs to extend the proximal and/or distal landing zone and to maintain side branch perfusion. Indication for treatment was a type Ia endoleak in 23 (96%) patients and a type Ib endoleak in one. Median interval from the previous EVAR to endoleak treatment with CPGs was 52.2±48.9 months (range 0.2–179). All patients had proximal/distal landing zones precluding any standa…

Malemedicine.medical_specialtyEndoleakmedicine.medical_treatmentparallel graftTarget vesselmorbidityperiscope graftEndovascular aneurysm repairpararenal aortic aneurysmSettore MED/22 - Chirurgia Vascolarelaw.inventionendovascular aneurysm repairBlood Vessel Prosthesis Implantationabdominal aortic aneurysmlawRecurrencethoracoabdominal aortic aneurysmMedicineHumansRadiology Nuclear Medicine and imagingIn patientChimneyself-expanding covered stentVascular PatencyAgedabdominal aortic aneurysm; chimney graft; endoleak; endovascular aneurysm repair; morbidity; mortality; parallel graft; pararenal aortic aneurysm; patency; periscope graft; reintervention; self-expanding covered stent; stent-graft; target vessel; thoracoabdominal aortic aneurysmreinterventionstent-graftbusiness.industryEndovascular ProceduresChimney graftchimney graftmedicine.diseasemortalityAbdominal aortic aneurysmSurgeryBlood Vessel ProsthesisSurvival RateTreatment OutcomeSurgeryFemalePeriscopeCardiology and Cardiovascular Medicinebusinesspatencytarget vesselAortic Aneurysm AbdominalJournal of endovascular therapy : an official journal of the International Society of Endovascular Specialists
researchProduct

Risk Burden of Coronary Perforation in Chronic Total Occlusion Recanalization: Latin American CTO Registry Analysis

2022

Background Coronary perforation is a life‐threatening complication of acute percutaneous coronary intervention (PCI) for chronic total occlusions (CTO), but data on midterm outcomes are limited. Methods and Results Data from LATAM (Latin American)‐CTO Registry (57 centers; 9 countries) were analyzed. We assessed the risk of 30‐day, 1‐year major adverse cardiac events of coronary perforation using time‐to‐event and weighted composite end point analysis having CTO PCI without perforation as comparators. Additionally, we studied the independent predictors of perforation in these patients. Of 2054 patients who underwent CTO PCI between 2015 and 2018, the median Multicenter CTO Registry in Japa…

Time Factorspercutaneous coronary interventionacute myocardial infarctionCoronary Angiographytarget vessel revascularization.Latin AmericaTreatment OutcomeHeart InjuriesRisk FactorsChronic DiseaseHumansProspective StudiesRegistriescoronary perforationCardiology and Cardiovascular Medicinechronic total occlusionJournal of the American Heart Association
researchProduct

Chimney and Periscope Grafts Observed Over 2 Years After Their Use to Revascularize 169 Renovisceral Branches in 77 Patients With Complex Aortic Aneu…

2013

Purpose: To evaluate the performance of periscope and/or chimney grafts (CPGs) in the endovascular treatment of pararenal or thoracoabdominal aneurysms using off-the-shelf devices. Methods: Between February 2002 and August 2012, 77 consecutive patients (62 men; mean age 7369 years) suffering from pararenal aortic (n¼55), thoracoabdominal (n¼16), or arch to visceral artery aneurysms (n¼6) were treated with aortic stent-graft implantation requiring chimney and/or periscope grafts to maintain side branch perfusion. CPGs were planned in advance and were not used as bailout. A standardized follow-up protocol including computed tomographic angiography, laboratory testing, and clinical examination…

aortic aneurysm pararenal aortic aneurysm thoracoabdominal aortic aneurysm aortic arch endovascular aneurysm repair renal artery superficial mesenteric artery celiac trunk target vessel stent-graft side branch chimney graft periscope graft parallel graft target vessel patency endoleak side branch occlusionSettore MED/22 - Chirurgia Vascolare
researchProduct

Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry.

2016

Aims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset, with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term, but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA), left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death, target vessel m…

LCX (29Target lesionMale52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostialp= 0.035)medicine.medical_treatmentMyocardial Infarction304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14Coronary Artery Disease030204 cardiovascular system & hematologyCoronary artery diseasebut their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA)0302 clinical medicineAbsorbable Implants030212 general & internal medicineMyocardial infarctionCircumflexRegistriesTissue Scaffolds32%)Drug-Eluting StentsMiddle AgedThrombosisCoronary VesselsAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA) left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death target vessel myocardial infarction or target lesion revascularisation. The database included a total of 1549 lesions in 1304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14; 16%) LCX (29; 32%) or LAD (47; 52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostial p= 0.618) post-dilation in 43% (versus 58% in the non-ostial group p= 0.008). At quantitative coronary angiography treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37] p= 0.035) but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groups respectively log-rank p= 0.005). The device-oriented composite endpoint occurred respectively in 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025 HR 2.65 [1.41-4.97]).OstiumAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subsetTreatment Outcomein 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025CardiologyFemale549 lesions in 1medicine.symptomCardiology and Cardiovascular MedicineAdultpost-dilation in 43% (versus 58% in the non-ostial groupmedicine.medical_specialtyor LAD (47HR 2.65 [1.41-4.97])but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groupsrespectivelyLesion03 medical and health sciencesPercutaneous Coronary Interventionwith higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long termleft anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular deathInternal medicinemedicineHumanstarget vessel myocardial infarction or target lesion revascularisation. The database included a total of 1Agedp= 0.008). At quantitative coronary angiographybusiness.industryPercutaneous coronary interventionp= 0.618)treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37]log-rank p= 0.005). The device-oriented composite endpoint occurredmedicine.diseaseSurgery16%)businessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

Sicilian DES Registry: prospective in-hospital and 9-month clinical and angiographic follow-up in selected high restenosis risk patients.

2008

OBJECTIVE: This is a multicentre, open label, prospective non-randomized registry, with 9-month angiographic follow-up, conducted to evaluate the safety and effectiveness of drug-eluting stents (DES) when used in high restenosis risk patients from the real world. METHODS: From June 2004 to February 2005, a total of 1622 consecutive patients were enrolled to the Sicilian DES Registry, according to specific inclusion criteria. Both paclitaxel-eluting and sirolimus-eluting stents were used. The analysis was performed on 1472 patients because 150 patients were excluded from the study. The primary endpoint was to evaluate the rate of major adverse cardiac events (MACE) within 9 months after DES …

Malemedicine.medical_specialtyPaclitaxelCoronary angioplastyRegistry.Target vessel revascularizationCoronary DiseaseCoronary AngiographyCoronary artery diseaseCoronary RestenosisRestenosisClinical endpointMedicineHumansCumulative incidencecardiovascular diseasesMyocardial infarctionDrug eluting stentRegistriesAngioplasty Balloon CoronarySicilyAgedSirolimusEjection fractionbusiness.industryIncidence (epidemiology)Drug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseSurgeryFemaleCardiology and Cardiovascular MedicinebusinessMaceDiabetic AngiopathiesImmunosuppressive AgentsJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct